Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 May 2010

Nozawa Keijirou, Watanabe Toshiaki

Abstract excerpt

For the patient in whom the Kras gene variation appears, cancer cell grow and continue to multiply even if blocked by EGFR inhibitor. A topping the offered figure effect of cetuximab is not accepted. The addition of cetuximab for treatment of metastatic colorectal cancer with Kras wild-type tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 20495308

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20495308-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].PMID 20495308Read ↗

[Prognostic role of KRAS mutation in colorectal cancer].Semantic proximity Read ↗

[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Semantic proximity Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

[The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].Semantic proximity Read ↗

[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].Semantic proximity Read ↗

Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer.Semantic proximity Read ↗

[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].Semantic proximity Read ↗

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].Semantic proximity Read ↗

[Anti-EGFR antibody therapy for colorectal cancer].Semantic proximity Read ↗

[KRAS mutation test].Semantic proximity Read ↗

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.Semantic proximity Read ↗

[Validation study of KRAS mutation in colorectal cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.